SCHEMBL4906791

SCHEMBL4906791

Cc1ccc(S(=O)(=O)NCCSc2nc(-c3ccccc3)cs2)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
PHGDH O43175 5/20 0.45
HTR1A P08908 1/20 0.45
HTR2A P28223 1/20 0.45
HTR7 P34969 1/20 0.45
HPGD P15428 1/20 0.45
MAPT P10636 4/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
MAPK1 P28482 3/20 0.43
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
MCL1 Q07820 1/20 0.42
MEN1 O00255 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4902435 0.93 TSHR (0.49) LMNANPC1RAB9ATDP1SMN1; SMN2
SCHEMBL4905491 0.90 RAB9A (0.45) LMNANPC1RAB9ATDP1SMN1; SMN2
SCHEMBL4901797 0.84 TSHR (0.48) LMNANPC1RAB9ATDP1SMN1; SMN2
SCHEMBL4906166 0.82 MAPT (0.55) LMNANPC1RAB9ASMN1; SMN2HPGD
SCHEMBL4894575 0.81 LMNA (0.54) LMNANPC1RAB9ASMN1; SMN2HPGD
SCHEMBL4899227 0.77 LMNA (0.53) LMNASMN1; SMN2HTR7HPGDMAPT
SCHEMBL4906794 0.76 NPC1 (0.42) LMNANPC1RAB9ATDP1SMN1; SMN2
SCHEMBL4904264 0.76 ALOX5 (0.55) LMNASMN1; SMN2HPGDMAPTALDH1A1
SCHEMBL4906189 0.74 LMNA (0.45) LMNANPC1RAB9ASMN1; SMN2HPGD
SCHEMBL4905936 0.74 SMN1; SMN2 (0.54) LMNANPC1RAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds HAMANAKA ERNEST S 2006-10-12 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARA, PPARG, PPARD LMNA 317/4885NPC1 50/4885RAB9A 2581/4885
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD LMNA 319/4885NPC1 59/4885RAB9A 2271/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD LMNA 319/4885NPC1 59/4885RAB9A 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.